A unique and promising therapeutic target is Six-Transmembrane Epithelial Antigen of the Prostate (STEAP), a family of metalloproteinases that are variably expressed in normal prostate tissue and, except STEAP3, overexpressed in PCa [4]. The gene discussed is STEAP3; the disease is posterior cortical atrophy.